About

About

OUR COMPANY

Tarsier® Pharma is a late clinical-stage company dedicated to the development and commercialization of a breakthrough therapeutic approach for better and safer treatment of autoimmune and inflammatory ocular diseases. The Dazdotuftide (TRS) Platform Technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections.

Ocular inflammations are a group of diseases affecting the front and back of the eye. Non-infectious anterior and posterior uveitis are the most known ocular inflammatory diseases. However, ocular inflammation is a critical underlying mechanism in the pathology of other inflammatory eye diseases, such as non-evaporative dry eye, diabetic macular edema (DME), and dry age-related macular degeneration (AMD). Hundreds of millions of people in all age groups are suffering from ocular inflammatory diseases worldwide, conditions that pose severe risks of vision loss and blindness.

With a leadership comprised of a global team of experienced, motivated, and dedicated professionals, and backed by investors who are focused on strategic investments in ophthalmology, we plan to leverage our new immunomodulatory approach to disrupt how ocular inflammatory diseases are being treated.

LEADERSHIP TEAM

Arie
Ganot

CPA | CFO

Daphne
Haim-Langford

PhD | Founder & CEO

Ron
Neumann

MD | CMO

Zohar
Milman

M.Sc | COO

in memory of Chaim Eidelman
1955-2022

PhD | Chief Chemist

Natan
Haykin

M.Sc | Head of CMC

 BOARD OF DIRECTORS

Atul Raut

Board Member

Susan K. Benton

Board Member

Daphne Haim-Langford

Board Member

Sascha Bucher

Board Member

SCIENTIFIC ADVISORY  BOARD

Prof. Marc
de Smet

MD, PhD | Advisory
board

Prof. H. Nida
Sen

MD, MHSc | Advisory
board

Prof. Quan
Dong Nguyen

MD, MSc | Advisory
board

Prof. Jennifer
Thorne

MD, PhD | Advisory
board

Prof. Emmett
Cunningham

MD, PhD | Advisory
board

Scroll to Top